drugset / Trial / NCT00584870

RN624 In Adult Patients With Chronic Low Back Pain

NCT00584870

Phase 2 Completed 220 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the analgesic efficacy of RN624 compared with placebo and compared with naproxen in the treatment of adult patients with chronic low back pain.

Timeline

Start
2007-07-05
Primary completion
2008-09-02
Completion
2008-09-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg Oral
Subject Tanezumab Monoclonal antibody 200 ug/kg Intravenous

Indications

No indication recorded.